|
Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
|
15 November 2022 |
|
Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
|
01 September 2022 |
|
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
|
08 July 2022 |
|
Foundation S: Sanofi's new philanthropic spearhead
|
04 May 2022 |
|
Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board
|
12 April 2022 |
|
Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
|
18 March 2022 |
|
Sanofi completes acquisition of Amunix
|
09 February 2022 |
|
Sanofi unveils new corporate brand and logo - unites the company under one purpose and a single identity
|
07 February 2022 |
|
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
|
20 January 2022 |
|
Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
|
26 November 2021 |